C188-9 (TTI-101) is currently undergoing clinical evaluation (Table 3) for the treatment of metastatic HR+/HER2-breast cancer in patients who have developed resistance to first-line palbociclib plus AI therapy (NCT05384119). This evidence concerns the gene ERBB2 and breast carcinoma.